1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. DOI: 10.1038/jid.2012.339
2. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):685-705. DOI: 10.1586/14737167.2014.933671
3. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874-888. DOI: 10.18553/jmcp.2015.21.10.874
4. Hawro T, Zalewska A, Hawro M, Kaszuba A, Królikowska M, Maurer M. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol. 2015;29(3):438-443. DOI: 10.1111/jdv.12572
5. Global Burden of Disease 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. DOI: 10.1016/S0140-6736(18)32279-7
6. Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study. Front Med (Lausanne). 2021;8:743180(1-12). DOI: 10.3389/fmed.2021.743180
7. Кубанов А.А., Богданова Е.В. Ресурсы и результаты деятельности медицинских организаций, оказывающих медицинскую помощь по профилю “дерматовенерология”, в Российской Федерации в 2016-2022 гг. Вестник дерматологии и венерологии. 2023;99(4):18-40. DOI: 10.25208/vdv12385
8. World Health Organization. Global report on psoriasis. 2016. URL: https://apps.who.int/iris/handle/10665/204417 (accessed: 30.12.2022).
9. Armstrong A, Bohannan B, Mburu S, Alarcon I, Kasparek T, Toumi J, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12(4):1055-1064. DOI: 10.1007/s13555-022-00695-0
10. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185. DOI: 10.1001/jamadermatol.2013.5264
11. Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881.e1-30. DOI: 10.1016/j.jaad.2013.12.018
12. Duffin KC, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014;170(3):672-680. DOI: 10.1111/bjd.12745
13. Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative Psoriasis Area and Severity Index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020;31(5):470-475. DOI: 10.1080/09546634.2020.1746734
14. Seidl U, Pinter A, Wilsmann-Theis D, Poortinga S, Morrison K, Mrowietz U, et al. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. Dermatol Ther. 2022;35(1):e15193. DOI: 10.1111/dth.15193
15. Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018;29(4):334-346. DOI: 10.1080/09546634.2017.1395794
16. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158-1166. DOI: 10.1111/bjd.18333
17. Псориаз: Клинические рекомендации Российского общества дерматовенерологов и косметологов. 2023 URL: https://cr.minzdrav.gov.ru/recomend/234_2 (accessed: 22.02.2023).
18. Бакулев А.Л., Фитилева Т.В., Новодережкина Е.А., Гиллотю И., Тиан Х., Ховэ Т., и др. Псориаз: клинико-эпидемиологические особенности и вопросы терапии. Вестник дерматологии и венерологии. 2018;94(3):67-76. DOI: 10.25208/0042-4609-2018-94-3-67-76
19. Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022;35(1):e15166. DOI: 10.1111/dth.15166
20. Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390-403. DOI: 10.1111/dth.12267
21. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology. 2012;225(4):326-332. DOI: 10.1159/000345715
22. Raam L, Hartmane I, Valiukevičienė S, Karamova AE, Telegdy E, Botev I, et al. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries. Front Immunol. 2024;15:1410540. DOI: 10.3389/fimmu.2024.1410540
23. Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol. 2013;149(5):577-582. DOI: 10.1001/jamadermatol.2013.1083
24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. DOI: 10.1111/j.1365-2230.1994.tb01167.x
25. Reilly Associates. Work Productivity and Activity Impairment Questionnaire (WPAI) Scoring. URL: http://www.reillyassociates.net/wpai_scoring.html (accessed: 30.12.2022).
26. Кубанов А.А., Богданова Е.В. Эпидемиология псориаза в Российской Федерации (по данным регистра). Вестник дерматологии и венерологии. 2022;98(2):33-41. DOI: 10.25208/vdv1268
27. Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535. DOI: 10.1002/14651858.CD011535.pub5
28. Kubanov AA, Bakulev AL, Fitileva TV, Novoderezhkina E, Gilloteau I, Tian H, et al. Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey. Dermatol Ther (Heidelb). 2018;8(4):581-592. DOI: 10.1007/s13555-018-0262-1
29. Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661-669. DOI: 10.1001/jamadermatol.2016.0269
30. Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67-76. DOI: 10.1016/j.jaad.2010.10.020
31. Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343-353.